Ulcer healing and Limb salvage
amputation, Gangrene, gangrene, ulcers, amputations, ulcer/gangrene, TAO, necrosis, ulcer, gangrenes, sores
THROMBOANGIITIS OBLITERANS, MINOR, WOUND INFECTION, GANGRENE, ULCERS, GANGRENE, NECROSIS, ISCHEMIC NECROSIS, SUPERINFECTION, ULCER, GANGRENES, TAO
Ten extremities completed the 6-month follow-up study. At baseline, nine limbs had non-healing sores, necrosis, and gangrene. Throughout the 6-month follow-up period, one limb demonstrated significant healing of the ulcer, and two limbs with ulcers and gangrenes did not progress and remained entirely dry. We performed minor amputations in one patient before cell treatment and five patients after P-MSC implantation, whose wounds healed after amputation, and the total ulcer surface measurement was largely reduced (Fig. Representation of the treated limbs showing the progression of ischemic ulcer/gangrene throughout 6-month follow-up. Patient 3: a 41-year-old man with thromboangiitis obliterans (TAO), Rutherford IV presented with non-healing ulcers on the ankle and lateral midfoot healed completely at 6 months after P-MSC implantation. Patient 4: a 55-year-old man with TAO presented with gangrene of the first and second toes, and a history of amputation of the 3th and 4th toes showed clear healing of ischemic necrosis on foot after amputation at 6 months after P-MSC implantation. Patient 7: A 66-year-old men, TAO with Rutherford-III, initially advanced gangrene and wound infection who diagnosed as needing major amputation, get minor amputation after cellular therapy and whole ulcer surface measurement was largely decreased at 6 months after P-MSC implantation. Patient 9: a 62-year-old man with Rutherford IV (TAO) presented with non-healing ulcers at dorsum of the foot and gangrene of the toe, showed clear healing of ulcer. Gangrene did not progress during the 6-month follow-upAt the six-month follow-up, the amputation rate in this trial was 40% (4 of 10 limbs). Of the nine patients, four underwent amputation, three of whom were diagnosed as needing major amputation. Referring clinicians concur that the first therapeutic approach is no longer effective following P-MSC therapy. Hence, they underwent minor amputation. Only one patient underwent major amputation (due to superinfection at the gangrene site) on day 70 after cell therapy and was excluded from the trial before the end of follow-up.